Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $223.28 million. The enterprise value is $214.99 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 55.68 million shares outstanding. The number of shares has increased by 10.61% in one year.
| Current Share Class | 55.68M |
| Shares Outstanding | 55.68M |
| Shares Change (YoY) | +10.61% |
| Shares Change (QoQ) | +15.56% |
| Owned by Insiders (%) | 10.66% |
| Owned by Institutions (%) | 17.48% |
| Float | 46.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 206.36 |
| P/TBV Ratio | 374.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 16.99.
| Current Ratio | 1.12 |
| Quick Ratio | 1.05 |
| Debt / Equity | 16.99 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.74 |
Financial Efficiency
Return on equity (ROE) is -247.78% and return on invested capital (ROIC) is -65.78%.
| Return on Equity (ROE) | -247.78% |
| Return on Assets (ROA) | -22.10% |
| Return on Invested Capital (ROIC) | -65.78% |
| Return on Capital Employed (ROCE) | -49.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.58M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $75,000 in taxes.
| Income Tax | 75,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.50% in the last 52 weeks. The beta is 1.04, so QNCX's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | +100.50% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 81.01 |
| Average Volume (20 Days) | 1,105,534 |
Short Selling Information
The latest short interest is 1.37 million, so 2.45% of the outstanding shares have been sold short.
| Short Interest | 1.37M |
| Short Previous Month | 1.31M |
| Short % of Shares Out | 2.45% |
| Short % of Float | 2.94% |
| Short Ratio (days to cover) | 4.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -41.80M |
| Pretax Income | -56.90M |
| Net Income | -56.98M |
| EBITDA | -41.68M |
| EBIT | -41.80M |
| Earnings Per Share (EPS) | -$1.21 |
Full Income StatementBalance Sheet
The company has $26.29 million in cash and $17.99 million in debt, giving a net cash position of $8.30 million or $0.15 per share.
| Cash & Cash Equivalents | 26.29M |
| Total Debt | 17.99M |
| Net Cash | 8.30M |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 1.06M |
| Book Value Per Share | 0.02 |
| Working Capital | 3.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.50 million and capital expenditures -$481,000, giving a free cash flow of -$38.98 million.
| Operating Cash Flow | -38.50M |
| Capital Expenditures | -481,000 |
| Free Cash Flow | -38.98M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |